Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

@article{Crawford2018AndrogenRT,
  title={Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens},
  author={D. Crawford and P. Schellhammer and D. Mcleod and J. Moul and C. Higano and N. Shore and L. Denis and P. Iversen and M. Eisenberger and F. Labrie},
  journal={The Journal of Urology},
  year={2018},
  volume={200},
  pages={956–966}
}
Purpose Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made… Expand
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Targeting the androgen receptor in prostate cancer
  • Z. Culig
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2014
Androgen pathway resistance in prostate cancer and therapeutic implications
Androgen receptor: structure, role in prostate cancer and drug discovery
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
  • D. Rathkopf, M. Morris, +11 authors H. Scher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
...
1
2
3
4
5
...